Bill Ackman and Concentrated Activist Investing

Bill Ackman pioneered a new brand of hedge fund activism: take a large, illiquid equity stake in a company he believes is mismanaged or undervalued, publish a detailed investment thesis as a public letter, and then pressure the board and management through media, shareholder campaigns, and proxy contests to enact change. His strategy married conviction, leverage, and transparency in ways that made him wealthy and, to many executives, infamous.

The activist mandate: Why size matters

Traditional hedge funds buy stocks they believe will rise and short stocks they believe will fall. Ackman borrowed this structure but inverted its psychology. He would acquire 5, 10, or even 15 percent of a public company’s shares—enough to be a material shareholder but below the threshold that triggers mandatory disclosure rules (though he often disclosed anyway for strategic effect). Then he would announce himself.

The key innovation was publicity. Rather than agitate quietly, Ackman would publish a detailed letter to shareholders, often 100+ pages, outlining the company’s dysfunction and his vision for value creation. He would highlight incompetent or conflicted management, bloated cost structures, strategic missteps, and the opportunity for rectification. The letter would be accompanied by media interviews, presentations to other investors, and, often, a sustained public campaign.

This strategy required enormous position sizes and deep conviction. If Ackman took a 10 percent stake in a $10 billion company, he was committing roughly $100 million of capital. If the company took three years to reform—or refused to—that capital was at risk. But that size also gave him leverage: a 10 percent shareholder could credibly threaten a proxy fight, forcing a shareholder vote to replace the board if management refused to negotiate.

Thesis-driven conviction and timing

Ackman’s early successes came from clear, thesis-driven cases. At CP&L, he identified a regional utility with a bloated cost structure and suboptimal capital allocation. He shorted the company—a bet that the stock would fall—and won. At Home Depot, he took a long position (betting the stock would rise), published a letter criticizing management’s strategy, and waited for change. Management eventually improved execution, and the position paid off.

What distinguished Ackman was his willingness to wait. Most investors held positions for months or quarters. Ackman held campaigns for years, sometimes holding enormous positions through earnings seasons, board meetings, and slow-motion management transitions. This required capital discipline and conviction—the same resources Stanley Druckenmiller brought to macro betting, but applied to corporate governance rather than currency cycles.

His timing sense was uneven. In some cases—Allergan (a pharmaceutical company), MBIA (mortgage insurers)—he identified genuine problems but arrived too late, or the solutions took longer than expected. In others, like his long position on the stock market and the real estate recovery post-2008, he rode major cycles profitably.

The power of public disclosure

Ackman’s genius was recognizing that transparency could be a weapon. By publishing his thesis publicly, he forced dialogue with management but also built pressure from regulators, media, and other investors. If Pershing Square published evidence of accounting issues or self-dealing at a company, journalists would investigate, sell-side analysts would reassess, and the stock would react—often in Ackman’s favour.

This model worked best when the thesis was clean and the company’s failings were genuinely dramatic. At Allergan, Ackman highlighted activist investing governance concerns and strategic missteps. At Valeant Pharmaceuticals (a major short position), he publicized accounting irregularities and unethical pricing that, when investigated by journalists and regulators, imploded the company. His early presentation on the short ran to 147 slides of detailed forensic analysis—not subtle, but devastating.

The downside was reputational: companies and their defenders attacked Ackman as a self-serving activist enriching himself by destroying shareholder value. When his shorts succeeded but the company faced criminal prosecution or financial collapse, critics blamed Ackman’s revelations rather than management’s misconduct. Ackman accepted this trade-off, arguing that exposing fraud protected future investors and capital markets integrity.

The Allergan saga and hedge fund activism at scale

Ackman’s 2017 campaign against Allergan, a pharmaceutical company, exemplified his method at its most granular and controversial. Pershing Square accumulated a 9 percent stake and published a detailed letter arguing that Allergan’s CEO and board were overpaid, the business strategy was flawed, and the company’s governance structure insulated them from accountability. Ackman called for a slate of new directors and a strategic re-evaluation.

The board resisted, but shareholder pressure mounted. Ultimately, Allergan’s CEO stepped down and management was reconstituted. From Ackman’s perspective, the campaign succeeded. From critics’ view, he had bullied a company and profited from the chaos. The truth, as usual, lay between: Allergan did have governance problems; shareholders did benefit from management change; Ackman’s fund did make enormous profits; and the company faced operational challenges independent of Ackman’s involvement.

This ambiguity reflects a deeper tension in activism: how much credit or blame belongs to the activist versus the company’s underlying fundamentals? Ackman sidesteps this by arguing that poor governance and strategy are underlying fundamentals—that boards exist to represent shareholders, and activists who pressure weak boards are performing a service.

Leverage, concentration, and the 2020s pivot

Ackman’s model worked best in the 2000s and 2010s, when capital was abundant, leverage was cheap, and public equity markets rewarded activists with patient capital. His Pershing Square funds ran heavily leveraged portfolios, sometimes deploying 1.5x or 2x capital relative to assets under management. This amplified gains in winning positions but magnified losses in losers.

The 2015 Pershing Square crash—driven by losses in Valeant and other concentrated shorts and longs—cost the fund roughly 20 percent. Ackman took the hit but remained confident in his method. A larger correction came in 2020 when COVID disrupted markets, but Ackman rotated the portfolio and recovered.

By the 2020s, Ackman’s public activism had muted. Pershing Square took smaller, less contentious stakes (including in Starbucks). Ackman transitioned toward more collaborative engagement with boards rather than public campaigns. Whether this reflected market learning—other activists had duplicated his playbook, reducing its edge—or personal preference remained unclear.

The legacy: Activism as governance tool

Ackman’s true legacy is institutional. He proved that an individual investor with a large stake, clear thesis, and public platform could force corporate boards to listen. This spawned a generation of imitators: other hedge funds adopted activist strategies; proxy advisory firms gained power; shareholders gained confidence in demanding change.

Whether this represents progress depends on your view. If activism corrects genuine mismanagement and aligns incentives, it strengthens markets. If it destabilizes sound companies for short-term gain, it corrupts them. Ackman would argue his thesis-driven approach—resting on detailed analysis of fraud or strategic missteps—falls into the former category. Critics note that many of his campaigns occurred when the broader market was pricing in recovery anyway, blurring causality.

See also